Trials / Completed
CompletedNCT01859962
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Presidio Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PPI-668 | |
| DRUG | BI 207127 Dose 1 | |
| DRUG | BI 207127 Dose 2 | |
| DRUG | Faldaprevir | |
| DRUG | Ribavirin | |
| DRUG | BI 207127 Placebo |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-05-01
- Completion
- 2014-12-01
- First posted
- 2013-05-22
- Last updated
- 2015-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01859962. Inclusion in this directory is not an endorsement.